Multicell Techs Inc (MCET) 0.0003 $MCET
MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application
PR Newswire - Wed Dec 10, 7:40AM CST
MultiCell Technologies, Inc. (OTC: MCET) has filed a U.S. patent application covering the design and therapeutic use of novel, next-generation antibody drug conjugates (ADCs) which provide for the simultaneous targeted delivery of multiple drugs from a single antibody.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.84 (unch), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), PVCT: 0.79 (-0.02), CANF: 3.85 (+0.05), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), XLRN: 38.02 (+0.07)
OTC Daily Trading News: Lamperd Less Lethal, Inc. MultiCell Technologies, Inc. Drone Aviation Holding Corp, ICTV Brands, Inc. Audio Eye, Inc.
PR Newswire Europe - Tue Aug 26, 9:08AM CDT
LONDON, August 26, 2014 /PRNewswire/ --
MultiCell Technologies awarded US patent for therapeutics that fight virus infection and cancer
M2 - Tue Aug 26, 7:04AM CDT
Biopharmaceutical company MultiCell Technologies (Other OTC:MCET) reported on Monday the receipt of the US patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer.
MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer
PR Newswire - Mon Aug 25, 7:51AM CDT
MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity.
MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application
PR Newswire - Wed Dec 10, 7:40AM CST
MultiCell Technologies, Inc. (OTC: MCET) has filed a U.S. patent application covering the design and therapeutic use of novel, next-generation antibody drug conjugates (ADCs) which provide for the simultaneous targeted delivery of multiple drugs from a single antibody.
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 3.84 (unch), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), PVCT: 0.79 (-0.02), CANF: 3.85 (+0.05), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), XLRN: 38.02 (+0.07)
OTC Daily Trading News: Lamperd Less Lethal, Inc. MultiCell Technologies, Inc. Drone Aviation Holding Corp, ICTV Brands, Inc. Audio Eye, Inc.
PR Newswire Europe - Tue Aug 26, 9:08AM CDT
LONDON, August 26, 2014 /PRNewswire/ --
MultiCell Technologies awarded US patent for therapeutics that fight virus infection and cancer
M2 - Tue Aug 26, 7:04AM CDT
Biopharmaceutical company MultiCell Technologies (Other OTC:MCET) reported on Monday the receipt of the US patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer.
MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer
PR Newswire - Mon Aug 25, 7:51AM CDT
MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity.
